William Blair analyst Adam Klauber has maintained their bullish stance on RYAN stock, giving a Buy rating on May 13.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Adam Klauber has given his Buy rating due to a combination of factors that support Ryan Specialty’s long-term outlook. He notes that management has been steadily expanding capabilities and product offerings to sustain organic growth across both favorable and unfavorable insurance cycles, and he believes recent deceleration in growth and guidance is likely near a trough.
Klauber also acknowledges that the shares may experience near-term swings as the property market environment deteriorates, yet he views the current valuation—about 12x projected 2027 EV/EBITDA, only a modest premium to slower-growing core brokerage peers—as attractive. In his view, this risk‑reward profile makes the stock compelling for investors with a long-term horizon.
Klauber covers the Financial sector, focusing on stocks such as Ethos Technologies Inc. Class A, Ehealth, and Erie Indemnity Company. According to TipRanks, Klauber has an average return of -4.0% and a 34.91% success rate on recommended stocks.
In another report released on May 13, Morgan Stanley also maintained a Buy rating on the stock with a $45.00 price target.